According to the company, a small group of trial subjects inadvertently received a half dose followed by a full dose, instead of the planned two full doses. A US study of AstraZeneca's vaccine involving some 30,000 volunteers is in the works and should produce data by late January. "My personal summation is that there seems to be effectiveness in the AstraZeneca vaccine from this other trial that provides optimism that the current trial in the United States will define that effectiveness," he said. AstraZeneca has said it is considering a new global trial based on the half dose first regimen. Should AstraZeneca decide to run a new U.S. trial testing the half dose first option, Corey said, the United States was unlikely to help foot the bill.

Source: bd News24 December 07, 2020 15:33 UTC